MedPath

Moderna Recruiting Participants for Norovirus mRNA Vaccine Clinical Trial

Moderna is currently seeking participants for its Nova 301 clinical trial, which focuses on developing an mRNA vaccine against norovirus, a common stomach bug.

Moderna is advancing its efforts in vaccine development by recruiting participants for the Nova 301 clinical trial. This trial is aimed at creating an mRNA vaccine to combat norovirus, a highly contagious virus that causes gastroenteritis, leading to stomach pain, nausea, diarrhea, and vomiting. The initiative represents a significant step forward in the fight against norovirus, which affects millions of people worldwide each year, causing significant health and economic burdens. The clinical trial is part of Moderna's broader strategy to utilize mRNA technology for the prevention of infectious diseases, building on the success of its COVID-19 vaccine. By targeting norovirus, Moderna hopes to provide a new tool in the global effort to reduce the incidence of this debilitating illness.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Moderna's mRNA Norovirus Vaccine Candidate Enters Phase 3 Trial Amidst Rising Cases

Moderna's norovirus vaccine candidate, mRNA-1403, is undergoing a Phase 3 clinical trial, Nova 301, with results expected as early as late 2025 or 2026.
The trial aims to enroll 25,000 adults to assess the vaccine's safety and efficacy against multiple norovirus genotypes, including those not directly targeted by the vaccine.

Moderna Begins Phase 3 COVE Study for COVID-19 mRNA Vaccine

Moderna, Inc. has initiated the Phase 3 COVE study of its mRNA vaccine candidate, mRNA-1273, against COVID-19, in collaboration with NIAID, NIH, and BARDA. The study aims to evaluate the vaccine's efficacy and safety, with plans to enroll approximately 30,000 participants in the U.S.

Clinical Trial Seeks Participants for Norovirus Vaccine Development in Nevada

Nevada Health Centers and Javara are collaborating to conduct clinical trials, starting in the Carson City area, to advance medical research.
A norovirus vaccine study is actively recruiting participants to develop an effective preventive measure against the highly contagious disease.

Merck and Moderna Launch Phase 3 Trial of mRNA-4157 plus Pembrolizumab in NSCLC

Merck and Moderna have initiated a Phase 3 clinical trial (INTerpath-009) to assess mRNA-4157 in combination with pembrolizumab for NSCLC.
The trial targets patients with resectable stage 2, 3A, or 3B (N2) NSCLC who did not achieve a pathological complete response after neoadjuvant therapy.

Phase 3 Trial Aims to Combat Norovirus with mRNA Vaccine in Adults

A Phase 3 clinical trial, Nova 301, is underway to evaluate an investigational mRNA vaccine's efficacy against norovirus in adults aged 18 and older.
The trial seeks to enroll approximately 25,000 participants globally, comparing the investigational vaccine to a placebo jab over a 25-month period.

Merck and Moderna Launch Phase 3 Trial of V940 (mRNA-4157) with Keytruda in NSCLC

Merck and Moderna have initiated a Phase 3 trial (INTerpath-009) to evaluate V940 (mRNA-4157) combined with Keytruda in NSCLC patients.
The trial targets patients with resectable Stage II, IIIA, or IIIB (N2) NSCLC who did not achieve a pathological complete response after neoadjuvant Keytruda and chemotherapy.

Merck and Moderna Advance mRNA-Based Cancer Therapy in Phase 3 Lung Cancer Trial

Merck and Moderna have initiated a Phase 3 trial (INTerpath-009) to evaluate V940 (mRNA-4157) combined with KEYTRUDA in resected Stage II-IIIB NSCLC patients.
The trial focuses on patients who did not achieve a pathological complete response (pCR) after neoadjuvant KEYTRUDA plus platinum-based chemotherapy.

Norovirus Vaccine Development Advances with mRNA and Oral Tablet Candidates

Moderna's mRNA-1403 vaccine demonstrated strong antibody responses against prevalent norovirus genotypes in early-phase trials, utilizing similar technology to their COVID and RSV vaccines.
An oral tablet vaccine, VXA-G1.1-NN, showed a 29% relative reduction in norovirus infection in a phase II trial, along with reduced viral shedding, though it did not meet its primary endpoint for preventing illness.

Mater Research Initiates Trial for Novavax's Combined COVID-19 and Flu Vaccine

Mater Research in Brisbane has begun a clinical trial for a combined COVID-19 and influenza vaccine developed by Novavax.
The protein-based, non-mRNA vaccine aims to protect individuals unable to receive mRNA vaccines by using a coronavirus spike protein segment to trigger an immune response.

Moderna's mRNA Norovirus Vaccine Enters Phase 3 Trial

Moderna's mRNA-1403 norovirus vaccine has entered a pivotal Phase 3 trial, evaluating its efficacy, safety, and immunogenicity in adults.
The global trial, named Nova 301, aims to enroll approximately 25,000 participants, focusing on adults aged 60 years and older.

Reference News

[1]
Moderna recruiting participants for Nova 301, norovirus mRNA vaccine clinical trial - Fortune
fortune.com · Jan 11, 2025

Fortune Media IP Limited holds rights to FORTUNE, a registered trademark. Site use implies acceptance of Terms, Privacy ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy